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requiring new surgery (BNI class I–IIIa). The new hypesthesia 
rate was 20.8% (median delay of onset = 12 months), and only 
1 patient (0.8%) reported very bothersome hypesthesia.  Con-
clusions: The long-term results were comparable to those 
from our general series (recently published), and the high 
probability of long-lasting pain relief and rarity of consequen-
tial complications of radiosurgery may suggest it as a first- 
and/or second-line treatment for classical, drug-resistant TN. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Trigeminal neuralgia (TN) is a rare disorder of the fifth 
cranial nerve and is considered one of the most excruciat-
ingly painful conditions that may be encountered in clin-
ical daily practice. The first-line therapy is pharmacolog-
ical (carbamazepine)  [1] . Any patients not responding to 
this medication or a short roster of other medications are 
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 Abstract 
 Background: Radiosurgery is one of the neurosurgical alter-
natives for intractable trigeminal neuralgia (TN).  Objective: 
Although acceptable short-/mid-term outcomes have been 
reported, long-term results have not been well documented. 
 Methods: We report the long-term results in 130 patients who 
underwent radiosurgery for classical TN and were subse-
quently monitored through at least 7 years (median = 9.9, 
range = 7–14.5) of follow-up.  Results: The median age was 
66.5 years. A total of 122 patients (93.8%) became pain free 
(median delay = 15 days) after the radiosurgery procedure 
(Barrow Neurological Institute, BNI class I–IIIa). The probabil-
ity of remaining pain free without medication at 3, 5, 7 and 10 
years was 77.9, 73.8, 68 and 51.5%, respectively. Fifty-six pa-
tients (45.9%) who were initially pain free experienced recur-
rent pain (median delay = 73.1 months). However, at 10 years, 
of the initial 130 patients, 67.7% were free of any recurrence 
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considered for surgery, including open microvascular de-
compression (MVD)  [2] or operative percutaneous abla-
tive procedures that deliberately generate a lesion on the 
trigeminal nerve in Meckel’s cave using physical, chemi-
cal or thermal agents  [3] . Radiosurgery  [4–7] , invented by 
the Swedish neurosurgeon Lars Leksell  [4] at the begin-
ning of the 1950s, targets the intracisternal trigeminal 
nerve  [8] with high doses of ionizing radiation and repre-
sents another surgical procedure that is distinguished 
from the percutaneous ones by its minimally invasive na-
ture  [9] . Due to the former, it is becoming increasingly 
used for medically refractory TN. Its safety and efficacy 
have been commonly demonstrated in short- and inter-
mediate-term follow-up studies  [7] , but only we and three 
other groups have reported long-term evidence of safety 
and efficacy  [6, 10–12] . 
 As radiosurgery has been sometimes criticized for not 
addressing very long-term outcomes in idiopathic TN, we 
felt the urge to address this crucial issue in the present 
manuscript. 
 Materials and Methods 
 Patient Population 
 Our study was designed to be open, self-controlled, noncom-
parative and prospective. A case report form was created and pro-
spectively used since the first patient was treated at Timone Uni-
versity Hospital, Marseille, France. Both a clinical examination 
and a magnetic resonance imaging (MRI) scan were done for all 
patients. The MRI was regarded as critical to exclude other pa-
thologies that can induce TN, such as benign or malignant intra-
cranial tumors, multiple sclerosis, vascular malformations, etc. 
The data were retrospectively analyzed. 
 Patients 
 Since July 1992 and until November 2010, 737 patients present-
ing with intractable TN were prospectively selected and treated 
with radiosurgery. A total of 130 consecutive patients treated be-
tween May 1993 and September 2003, all evaluated according to 
our prospective protocol, were followed up for more than 7 years. 
Patients with TN secondary to multiple sclerosis  [13] or megadol-
icho-basilar artery compression  [14] , or having had a second ra-
diosurgery  [15] , reputed to have more variable responses, were 
excluded. The Ethics Committee of the Timone University Hospi-
tal (CPPRB 1) approved our study. 
 Diagnostic Criteria Using the International Headache Society 
Definition 
 All patients fulfilled the criteria of the International Headache 
Society  [16] . Evaluation of the type of trigeminal pain was made 
according to the classification proposed by Eller et al.  [17] , com-
prising idiopathic TN1 and TN2. TN1 is described as typically 
sharp, shooting, electrical shock-like pain, with pain-free intervals 
between the attacks, that is present for more than 50% of the time; 
TN2 is described as an aching, throbbing or burning pain present 
for more than 50% of the time and that is constant in nature (con-
stant background pain being the most significant attribute). Only 
patients whose TN fulfilled the diagnostic criteria of TN1 were in-
cluded in this report. 
 Radiosurgical Technique 
 After the application of the Leksell Model G stereotactic frame 
(Elekta Instruments AB, Stockholm, Sweden) under local anesthe-
sia, all patients underwent MRI and computerized tomographic 
(CT) imaging for target definition. Two volumetric stereotactic 3D 
MRI sequences were used to identify the trigeminal nerve: milli-
metric noncontrast T2-weighted constructive interference steady-
state pulse sequences and millimetric contrast-enhanced T1-
weighted images. Skull base CT scans routinely supplemented 
these neuroradiological investigations in order to correct any dis-
tortion errors in the MRI studies  [8] .
 Between May 1993 and September 2003 Gamma Knife models 
B, C and 4C (Elekta Instruments AB) were successively used. A 
single 4-mm collimator helmet was used for all patients, and a ret-
rogasserian stereotactic target was positioned in the anterior cis-
ternal portion of the trigeminal nerve ( fig. 1 ) at a median distance 
of 8 mm (range = 4.9–14) anterior to the emergence of the nerve 
 [8] . This radiosurgical target location has been classically and con-
stantly used in our center throughout the time since we have treat-
ed the first patients for TN. 
 The median maximum dose delivered was 85 Gy (range = 70–
90). We initially prescribe a dose of 90 Gy to the 100% isodose. 
Beam channel blocking is used depending on the maximal dose 
received by 10 mm 3 of the brainstem. If this dose is >15 Gy, we 
decrease the prescribed dose, and then if still necessary we start 
plugging, making it possible for us to avoid the so-called ‘Flick-
inger effect’ (increasing the mean dose to the nerve increases toxic-
ity)  [18] . All interventions were performed by the senior neurosur-
geon (J.R.).
 Follow-Up Course 
 Initial follow-up consisted of a neurological evaluation at reg-
ular intervals of 3, 6, 9 and 12 months and on a yearly basis there-
after. This included facial sensory testing, corneal reflex and jaw 
motility. All patients were seen in person for the proper evalua-
tion of safety and efficacy, with a rigorous neurological examina-
tion, including the above-mentioned. For very long-term follow-
up updates, telephone interview were considered acceptable for 
patients who were unable to visit us either because of distance or 
general health conditions. The patients and the referring doctor 
were instructed to continue the medication unchanged for at 
least 1 month and then to diminish the drug doses progressively 
in the case of pain freedom. Every clinical evaluation made by our 
medical team during the follow-up course was prospectively not-
ed in the database so that we had continuous and prospectively 
collected up-to-date information. The 15 items of essential data 
for scientific literature reporting outcomes of the surgical treat-
ment of TN, as considered by Zakrzewska et al.  [19, 20] , were 
followed. 
 Explicit Definitions of Outcome Measures 
 Outcome measures included time to initial pain relief, the onset 
and timing of any sensory disturbance, the recurrence of pain and 
recurrence without further surgery. Initial pain relief was classified 
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according to the Barrow Neurological Institute (BNI) scale ( ta-
ble 1 )  [21] . The degree of hypesthesia was reported using the BNI 
facial hypesthesia scale  [21] ( table 1 ). The corneal reflex was as-
sessed for all patients. Additionally, the appearance or absence of 
dysesthesias, paresthesias, anesthesia dolorosa, masseter muscle 
weakness, neurological complications outside the trigeminal nerve 
territory, systemic complications or death was noted. 
 A recurrence was defined as a change from class I to a lower 
outcome class. A minor recurrence was considered as one well tol-
erated by the patient (lower frequency and intensity of the pain) 
and not necessitating a new surgical therapy. A major recurrence 
was defined as one requiring an additional open, percutaneous or 
radiosurgical procedure.
 Patient Satisfaction 
 Patient satisfaction was evaluated at the last follow-up. We 
used a semi-structured interview, conducted by the Gamma 
Knife team, during the follow-up visits. Responses in our semi-
structured questionnaire included: (1) No regret, I would un-
dergo radiosurgery again with no hesitation; (2) No opinion, or 
(3) I regret having had radiosurgery (and would not have it done 
again).
 Statistical Analysis 
 All statistical analyses were performed by two professional col-
leagues (the co-authors N.R. and J.G.) using the R software, ver-
sion 2.12.0 (R Foundation for Statistical Computing, Vienna, 
Austria). For the evaluation of outcomes such as freedom from 
pain, hypesthesia and recurrence, the time-to-event was estimated 
using the Kaplan-Meier method. A bivariate analysis was then 
performed to identify predictive factors among the collected vari-
ables. For qualitative variables, Kaplan-Meier curves were used to 
graphically represent survival among the different groups, and 
were compared using the univariate log-rank test. For all vari-
ables, the effects were estimated and tested by fitting univariate 
Cox proportional hazards regression models. The proportionality 
of hazards was assessed graphically by log-cumulative hazard 
plots. For qualitative variables, the χ 2 test was performed when 
valid; otherwise the Fisher exact test was used. The Mann-Whit-
ney test was performed for quantitative variables, given the num-
ber of patients. All tests were two-sided and p values <0.05 were 
judged to be significant.
 Results 
 Details of Follow-Up Period 
 The median follow-up period was 118.4 months 
(range = 84.2–174.4).
 Table 1.  Pain outcome assessment according to BNI scale and BNI 
facial hypesthesia scale
Description
Grade1, BNI pain intensity score
I No trigeminal pain, no medication
II Occasional pain, not requiring medication
IIIa No pain, continued medication
IIIb Persistent pain, controlled with medication
IV Some pain, not adequately controlled with medication
V Severe pain/no pain relief
Grade, BNI facial numbness score
I No facial numbness
II Mild facial numbness, not bothersome
III Facial numbness, somewhat bothersome
IV Facial numbness, very bothersome
1 Grade I–IIIa: significant pain relief; grade IIIb: adequate pain 
relief; grades IV and V are failures.
Draw of the trigeminal
nerve
Specific isodoses
showing the dose fall-off
45 Cy
15 Cy
Brainstem
7.5 mm 
 Fig. 1. Planning of a radiosurgical treatment by Gamma Knife for 
TN. The targeting of the cisternal portion of the prepontine trigem-
inal nerve (red; color in online version only) on the side of the pain 
is based on a T2-weighted high-resolution MRI. Distortions of the 
MRI are evaluated (and corrected if necessary) based on a stereotac-
tic CT performed the same day. The target is defined, in our group, 
at approximately 7.5 mm anterior to the emergence of the nerve. The 
selected dose at the maximum is typically 90 Gy but is decreased as 
low as 70 Gy in the case of high dosage potentially delivered to the 
brainstem due to the morphology of the cisternal anatomy. 
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 Basic Demographic Data 
 The preoperative clinical demographic data are shown 
in  table 2 . The median age was 66.5 years (range = 28.8–
89). In this series, 57 patients (43.8%) were men and 73 
(56.2%) were women. 
 The pain was on the right side in 67 patients (51.5%) 
and on the left side in 63 (48.5%). Only 4 patients (3.1%) 
had bilateral pain, but never simultaneously. Pain was 
predominantly distributed in the V2 territory of the tri-
geminal nerve (29.2%), followed by V3 (20%), V2 and V3 
(19.2%), V1 and V2 (16.9%), V1 (7.7%), and V1, V2 and 
V3 (6.9%). 
 The median time between pain onset and the radiosur-
gery treatment was 72.2 months (range = 1–387). Preop-
erative MRI revealed the presence of a neurovascular con-
flict in 74 cases (56.9%). 
 Data Regarding Previous Treatments  
 Gamma Knife radiosurgery was the first surgical pro-
cedure in 82 patients (63.1%). Forty-eight (36.9%) pa-
tients had prior surgical procedures and of these, 23 
(17.7%) had only 1 previous intervention, 17 (13.1%) had 
2 previous surgeries and 8 (6.1%) had 3 or more previous 
surgeries. Previous surgeries consisted of radiofrequency 
lesioning in 26 patients (20%), balloon microcompres-
sion in 22 patients (16.9%), MVD in 10 patients (7.7%) 
and glycerol rhizotomy in 3 patients (2.3%). All patients 
had drug-resistant TN or major intolerance to all phar-
macological therapies. Sixty-eight patients (52.3%) re-
ported substantial side effects of drug therapy at the time 
of radiosurgery.
 Data of Side Effects Related to Prior Surgical 
Interventions 
 Before radiosurgery, 29 patients (22.3%) had a sensory 
disturbance consequent to a previous surgical procedure 
and/or their TN, consisting of slight hypesthesia in 26 
cases (20%) and severe hypesthesia in 3 (2.3%). 
 Probability of Freedom from Pain after Radiosurgery 
 A total of 122 patients (93.8%) became pain free after 
the Gamma Knife radiosurgical procedure with or with-
out medication (BNI classes I–IIIa, median delay to pain 
relief = 15 days, range = 0–180). The initial pain freedom 
rate at 0.5, 1, 2, 3, 4, 5 and 6 months was 54.6, 73.9, 86.2, 
89.2, 90, 90.8 and 92.3%, respectively. The probability of 
becoming pain free after radiosurgery was dependent on 
the time since radiosurgery and reached a plateau at 6 
months ( fig.  2 a). The duration of pain before Gamma 
Knife (p = 0.73), the sex of the patient (p = 0.56) and the 
effect of a prior surgery (p = 0.33 for one, p = 0.55 for two, 
p = 0.09 for three or more) were not statistically signifi-
cant. Previous MVD (p = 0.01) was already advocated as 
a negative predictor for initial pain relief in one of our 
previous studies [28] and applies also to the current one. 
 Sensory Dysfunction  
 No patient developed an early complication after ra-
diosurgery. Overall, 21 of 101 patients (20.8%) without 
previous facial sensory symptoms developed new sensory 
dysfunction later, such as paresthesias or objective facial 
sensory loss, which occurred most frequently during the 
first 5 years after radiosurgery ( table 3 ). The actuarial rate 
of developing new hypesthesia was 19.8% at 5 years, 
 Table 2.  Clinical preoperative demographic data (n = 130)
Sex
Male
Female
57 (43.8)
73 (56.2)
Age, years 66.5 (28.8 – 89)
Duration of follow-up, months 118.4 (84.2 – 174.4)
Side of pain
Right
Left
Bilateral
67 (51.5)
63 (48.5)
4 (3.1)
Pain distribution
V2
V3
V2 and V3
V1 and V2
V1
V1–V3
38 (29.2)
26 (20)
25 (19.2)
22 (16.9)
10 (7.7)
9 (6.9)
Preoperative MRI vascular conflict (other 
than megadolichobasilar compression) 74 (56.9)
No prior surgery 82 (63.1)
Prior surgery
1
2
≥3
48 (36.9)
23 (17.7)
17 (13.1)
8 (6.1)
Type of prior surgery 
Radiofrequency lesion 
Balloon microcompression
MVD
Glycerol rhizotomy
26 (20)
22 (16.9)
10 (7.7)
3 (2.3)
Side effects from prior surgery 32 (24.6)
Facial sensibility before Gamma Knife 
radiosurgery
Normal
Slight hypesthesia
Severe hypesthesia
Anesthesia
101 (77.7)
26 (20)
3 (2.3)
0 (0)
Data are presented as n (%) or median (range), as appropriate.
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reached 20.8% at 7 years, and remained stable until 14 
years ( fig.  2 b). Among those experiencing hypesthesia, 
the median interval between radiosurgery and the onset 
of hypesthesia was 12 months (range = 0.5–65). Accord-
ing to the BNI facial hypesthesia scale, facial numbness 
was mild in 19 patients (18.8%), somewhat bothersome 
in 1 patient (0.8%), and very bothersome in 1 patient 
(0.8%). 
0.8
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 Fig. 2. Probability of being initially pain free and having new hyp-
esthesia onset depending on time since radiosurgery.  a The prob-
ability of becoming pain free reaches a plateau at 6 months (with a 
pain freedom rate of 92.3%). Rates of freedom from pain as well as 
the number of patients at risk of the event, the number that achieve 
the event, the survival rate and the standard error, as well as the 
lower and upper 95% CI were calculated. The initial pain-free rate 
at 0.5, 1, 2, 3, 4, 5, 6 months was 54.6, 73.9, 86.2, 89.2, 90, 90.8 and 
92.3%, respectively.  b The probability of new hypesthesia reached 
a plateau at 5 years (with a hypesthesia rate of 20.8%).  c ,  d The 
probability of maintaining pain relief without medication ( c ) and 
the probability of maintaining pain relief without requiring new 
surgery (minor recurrence,  d ) depending on the time since pain 
cessation. The rate of pain freedom without medication ( c ) at 3, 5, 
7, 10 and 12 years was 77.9, 73.8, 68, 51.5 and 46.4%, respectively. 
The rate of pain freedom without new surgical treatment ( d ) at 3, 
5, 7, 10 and 12 years was 83.6, 80.3, 75.4, 67.7 and 67.7%, respec-
tively. 
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 The majority of the patients considered that their qual-
ity of life improved after radiosurgery and that the sen-
sory dysfunction, when present, was a good trade-off for 
pain relief. Only 3 patients (2.3%) reported that their 
quality of life was worse and that sensory dysfunction was 
not a good trade-off. No patient developed a trigeminal 
motor deficit or other cranial nerve deficits after radio-
surgery.
 Probability of Pain Relief without Medication  
 The probability of achieving and maintaining pain re-
lief without medication at 0.5, 1, 2, 3, 5, 7, 10, 12 and 14 
years was 93.4, 85.9, 78.6, 71.8, 64.9, 59.7, 45.3, 40.7 and 
33.9%, respectively ( fig. 2 c). The probability of remaining 
pain free was higher, with a shorter delay between TN 
pain onset and radiosurgery [p = 0.04, hazard ratio 
(HR) = 1, 95% confidence interval (CI) = 0.99–1] but was 
not influenced by the development of postradiosurgery 
hypesthesia (p = 0.88) or the existence of a neurovascular 
conflict on MRI (p = 0.38), with the same applying to 
plugging (p = 0.14). Furthermore, an earlier initial re-
sponse predicted a better long-term benefit (p < 0.05). 
 Probability of Pain Relief Not Requiring New Surgery 
(Minor Recurrence) 
 The probability of achieving and maintaining pain re-
lief not requiring further surgery at 6 months and 1, 2, 3, 
5, 7 and 10 years was 94.3, 90.2, 87.7, 83.6, 80.3, 75.4 and 
67.7%, respectively, and remained stable until 14 years 
( fig. 2 d). Maintaining pain relief without further surgery 
was significantly associated with the presence of postra-
diosurgery hypesthesia (p = 0.04, HR = 0.13, 95% CI = 
 Table 3.  Postoperative assessment and patient satisfaction survey: the opinion of the patients about the benefit 
provided by radiosurgery (n = 130)
Initially pain free 122 (93.8)
Postradiosurgical sensory dysfunction
Mild
Severe
21 (16.1)
15 (11.5)
6 (4.6)
BNI facial hypesthesia scale
No facial numbness
Mild facial numbness
Facial numbness, somewhat bothersome
Facial numbness, very bothersome
109 (83.8)
19 (18.8)
1 (0.8)
1 (0.8)
Recurrence of pain 56/122 (45.9)
Time to pain recurrence, months 73.1 (0.9 – 150.1)
Additional treatments after Gamma Knife radiosurgery
1
2
≥3
Balloon microcompression
Radiofrequency lesion 
MVD
Cortical stimulation
Gamma Knife radiosurgery
42 (32.3)
28 (21.5)
10 (7.7)
4 (3.1)
22 (16.9)
11 (8.5)
9 (6.9)
1 (0.8)
8 (6.1)
Opinion of the patient
No regret, I would undergo radiosurgery again with no hesitation
No opinion
I regret having had radiosurgery (and would not have it done again)
121 (93.1)
6 (4.6)
3 (2.3)
 Data are presented as n (%) or median (range), as appropriate. The vast majority (93.1%) expressed a high 
level of satisfaction, did not regret performing radiosurgery and would undergo it again. In contrast, 3 patients 
were not satisfied with the result of radiosurgery and would not accept having the procedure nowadays. One of 
these dissatisfied patients got no pain relief while experiencing nondisabling hypesthesia; 1 patient who had un-
dergone several operations before radiosurgery (1 MVD and 2 thermocoagulations) and who had facial hypes-
thesia before Gamma Knife radiosurgery experienced a good therapeutic effect from the radiosurgery, but had a 
frank worsening of his preexisting hypesthesia; the third patient underwent a thermocoagulation before Gamma 
Knife radiosurgery, and because he had only a transient benefit from radiosurgery he received MVD and a second 
thermocoagulation and ultimately developed neuropathic pain.
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0.02–0.98). Conversely, recurrence with the need for fur-
ther surgery was statistically associated with bilaterality of 
the preradiosurgery pain (p = 0.03, HR = 3.59, 95% CI = 
1.1–11.73) and pain within the V3 territory (p = 0.05, 
HR = 2.92, 95% CI = 0.99–8.62)
 Management of Recurrent Pain 
 Fifty-six patients (45.9%) who were initially pain free 
experienced at least one recurrence with a median delay 
of onset of 73.1 months (range = 0.9–150.1). Fourteen 
patients had only minor recurrences, as their pain could 
be adequately managed with medication. Medically re-
fractory (‘major’) pain recurred in 42 patients (32.3%) 
who required further surgery. Twenty-eight patients 
(66.7%) required only 1 further surgery, 10 (23.8%) re-
quired 2 further surgeries and 4 (9.5%) required 3 or 
more surgeries ( table 3 ). In our center, the most com-
mon intervention after failed radiosurgery was balloon 
compression rhizotomy (22 patients, 52.4%), followed 
by radiofrequency thermorhizotomy (11 patients, 
26.2%), MVD (9 patients, 21.4%), repeated radiosur-
gery (8 patients, 19%) and cortical stimulation (1 pa-
tient, 2.4%). In general, if a first-intention MVD treat-
ment was proposed but declined by the patient, it was 
usually suggested a second time and frequently accept-
ed by the patient in cases when radiosurgery was not 
efficacious. 
 Discussion 
 Physician and patient interest in radiosurgery as a 
first- and/or second-line therapy in medically refractory 
TN has consistently grown, especially after the corner-
stone paper published by Kondziolka et al.  [22] , which 
fomented ‘a revolution in functional neurosurgery’  [7] . 
The mechanisms of action of radiosurgery for TN are not 
completely elucidated, but it seems to primarily affect 
myelin at the radiosurgery site  [23] . Clinical evidence ex-
ists nowadays for factors that predict for a lower degree 
of radiosurgery efficacy, including multiple sclerosis  [13] , 
previous MVD  [24] , previous surgical treatment on the 
same side  [8] or atypical TN.
 The current literature includes few studies with long-
term follow-up  [6, 7, 10, 11] . In chronological order, in 
2009, Dhople et al.  [10] reported a series of 102 patients 
with a median follow-up period of 5.6 years. Although 
they presented comparable rates to those published to 
date in terms of achieving freedom from pain (81%), 
bothersome hypesthesia was as high as 6%, and they re-
ported rather disappointing durably positive results (only 
22%) at 7 years. In 2010, Kondziolka et al.  [6] published 
a series from Pittsburgh, with a rather low rate of hypes-
thesia (10.5%) and a 10-year rate of 29% of patients who 
were pain free without medication. We recently reported 
our results  [11] in a series of 497 patients with more than 
one-year follow-up (median = 43.8 months, range = 28.1–
93.2). After a very good initial response (91.75%), 45.3% 
of patients were still pain free without medication at 10 
years. In that series, the hypesthesia rate was 21.1%, with 
a plateau reached at 7 years, which remained stable for up 
to 14 years. Additionally, very bothersome hypesthesia 
was reported in only 3 patients (0.6%). 
 To the best of our knowledge, the present study is the 
first to report very long-term follow-up with a large num-
ber of patients (n = 130). Initial pain relief was reported 
by 93.8% of patients, with a median delay of 15 days after 
radiosurgery. The new hypesthesia rate was low, at 20.8% 
(with a median delay of onset of 12 months after radio-
surgery), with only 1 patient (0.8%) reporting very both-
ersome hypesthesia. The probability of remaining pain 
free at 10 years was 51.5%. An added value of our analysis 
is the reporting of the actuarial rate of patients free of any 
recurrence requiring new surgery: 67.7% at 10 years after 
radiosurgery. 
 As for the other surgical techniques, MVD, pioneered 
by Peter Jannetta, is presently considered the reference 
procedure, as it addresses the cause (e.g. the vascular loop 
compressing the nerve). It mainly consists of a small cra-
niotomy to facilitate exposure and access to the nerve 
where it exits the brainstem. After identifying the offend-
ing vascular loop, this is separated by the nerve using a 
small Teflon pad. In the largest published series (Barker 
et al.  [2] ), with a median follow-up of 6.2 years, the initial 
rate of achieving freedom from pain was 98%, with 82% 
being completely pain free. After 10 years, 70% still had 
an excellent response (pain relief without medication). 
Severe facial numbness was encountered in 1.8%, and 
major complications included, in decreasing order, 
chemical meningitis (19%), cerebrospinal fluid leak 
(1.7%), ipsilateral hearing loss (1.3%), extraocular muscle 
palsy (1.2%) and facial palsy, etc. (1%), with a very low, 
but nonzero postoperative death rate (0.2%). 
 Percutaneous techniques are ablative, as they act by 
causing a destruction of the nerve fibers, either by ther-
mal energy (radiofrequency rhizotomy) or by chemical 
(glycerol rhizotomy) or mechanical damage (balloon mi-
crocompression). In this context, they commonly cause 
facial numbness to varying degrees, as a condition for 
complete and prolonged efficacy. They are generally 
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straightforward and safe, and are performed in the oper-
ating room. The initial pain relief rates range between 90 
and 97.6% for all these techniques, and at 3 years the pain 
relief rate falls to between 53 and 69%, with severe numb-
ness occurring in up to 20–23% of patients. These proce-
dures are notable for high recurrences rates (as high as 
26% at a very short mean time of 18 months)  [3, 25–27] . 
Additionally, other procedure-associated complications 
include exposure keratitis (0–2%), anesthesia dolorosa 
(0–2.5%), troublesome dysesthesias (4–10%) and masti-
catory weakness (0–12%)  [3, 25–27] .
 The most commonly performed functional neurosur-
gery procedure is for TN, representing up to 90% of all 
such procedures, including those in our center. There 
have been technical refinements over time which aimed 
at improving the safety and efficacy. Hypesthesia is not 
mandatory for achieving and maintaining pain relief, 
pointing out the fact that radiosurgery is not an ablative 
procedure. Patient satisfaction in our series was good, 
since 93.1% expressed a high level of satisfaction. The 
present study gives an overview of radiosurgical results 
on the basis of the very long-term follow-up. With an im-
portantly large cohort of patients and an extended follow-
up period, it provides a worthy comparison to our global 
series  [11] , providing evidence of high safety and efficacy 
of radiosurgery in idiopathic TN.
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